// App-Quantinova.ai

580 : Anti-EGFRvIII TandAbs recruiting either T or NK cells are highly specific and potent therapeutic antibody candidates for the treatment of EGFRvIII+ tumors

Researchers

Presenter

  • Kristina Ellwanger

Principal Investigators

  • Uwe Reusch

  • Ivica Fucek

  • Michael Weichel

  • Thorsten Gantke

  • Stefan Knackmuss

  • Martin Treder

Medical Centers

  • Affimed, Heidelberg, Germany

Locations

  • Germany

Companies

  • Affimed GmbH

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

  • Non Small Cell Lung cancer

  • Squamous cell carcinoma of the head and neck

Biomarkers

  • Natural Killer cells

  • Epidermal growth factor receptor

Drug/Treatment

  • Rindopepimut

  • Bevacizumab

  • EGFRvIII

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved